Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK's fourth-quarter results beat market estimate, sees 2024 growth
02:13am, Wednesday, 31'st Jan 2024
GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its shingles sh
GSK Reports Earnings Wednesday. Watch the RSV Vaccine Showdown.
05:30pm, Tuesday, 30'th Jan 2024
The U.K.-based company is looking to recover after a lackluster 2023.
3 Hidden Healthcare Stocks Poised for a Breakout This Year
12:31pm, Tuesday, 30'th Jan 2024
One of the most important sectors not only in the financial markets but also in everyone's life, is the healthcare sector. It can provide investors with good returns due to its constant growth and con
Is a Surprise Coming for GSK This Earnings Season?
09:36am, Tuesday, 30'th Jan 2024
GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
12:56pm, Monday, 29'th Jan 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
GSK RSV vaccine achieves blockbuster status in just over six months
10:47am, Monday, 29'th Jan 2024
GSK PLC has seen its RSV vaccines shoot to blockbuster status in little over six months, according to the Financial Times citing analysts. The term blockbuster refers to any drug with annual sales of
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
01:06pm, Thursday, 25'th Jan 2024
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Thursday, 25'th Jan 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 24'th Jan 2024
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
05:36am, Wednesday, 24'th Jan 2024
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu
GSK (GSK) Stock Dips While Market Gains: Key Facts
07:06pm, Monday, 22'nd Jan 2024
GSK (GSK) closed at $39.53 in the latest trading session, marking a -0.38% move from the prior day.
GSK nets £978m from Haleon share sale
02:52am, Wednesday, 17'th Jan 2024
GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 milli
GSK raises $1.24 bln from latest Haleon stake sale
02:18am, Wednesday, 17'th Jan 2024
British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone con
GSK and AstraZeneca: A leading investment bank gives its verdict with an upgrade and a downgrade
12:02pm, Tuesday, 16'th Jan 2024
UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK i
GSK to sell 3.2% stake in spin-off Haleon
11:58am, Tuesday, 16'th Jan 2024
GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.
